Hamilton Thorne Ltd.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: CA4078911001
CAD
2.24
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hamilton Thorne Ltd. stock-summary
stock-summary
Hamilton Thorne Ltd.
Miscellaneous
Hamilton Thorne Ltd. is engaged in the development, manufacture and sale of precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell and developmental biology research markets. The Company offers Clinical lasers, Research lasers and Clinical Sperm Analysis Products. Its Clinical lasers include LYKOS laser and ZILOS-tk laser for applications, such as laser-assisted hatching and embryo biopsy for pre-implantation genetic diagnosis (PGD). Its Research lasers include XYRCOS laser, XYClone laser and Stiletto laser for applications, such as transgenic animal production, stem cell applications and somatic cell nuclear transfer. Its Clinical Sperm Analysis Products include IVOS II Clinical, CEROS II Clinical and Dimensions II Strict Morphology for applications, such as fertility testing, reproductive toxicology, and biological research. It also provides ZANDAIR air purification systems for in-vitro fertilization and pathology.
Company Coordinates stock-summary
Company Details
100 Cummings Ctr Ste 465e , BEVERLY MA : 01915-6143
stock-summary
Tel: 1 978 92120501 978 9212050
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Meg Spencer
Chairman of the Board
Mr. David Wolf
President, Chief Executive Officer, Director, IR Contact Officer
Dr. David Sable
Director
Mr. Dean Gendron
Independent Director
Mr. Bruno Maruzzo
Independent Director
Mr. Robert Potter
Independent Director
Mr. Marc Robinson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Sep 2024)
Net Profit:
-2 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

CAD 345 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.21

stock-summary
Return on Equity

-0.55%

stock-summary
Price to Book

3.91